Delivering curcumin and gemcitabine in one nanoparticle platform for colon cancer therapy

RSC Advances ◽  
2014 ◽  
Vol 4 (106) ◽  
pp. 61948-61959 ◽  
Author(s):  
Manhong Tan ◽  
Jia Luo ◽  
Ying Tian
Keyword(s):  
Colon Cancer ◽  
Cancer Therapy ◽  
Cancer Cells ◽  
Colon Cancer Cells

As gemcitabine and curcumin have different targets in colon cancer cells, combination of them may bring benefits.

scholarly journals Knockdown of Parkinson’s disease-related gene ATP13A2 reduces tumorigenesis via blocking autophagic flux in colon cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Qian Chen ◽  
Li Zhong ◽  
Chao Zhou ◽  
Yan Feng ◽  
Quan-xing Liu ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Colon Cancer ◽  
Parkinson's Disease ◽  
Cancer Therapy ◽  
Cancer Cells ◽  
Cancer Prognosis ◽  
Autophagic Flux ◽  
Colon Cancer Cells ◽  
Related Gene ◽  
Disease Related Gene

Abstract Background Accumulating evidence shows that Parkinson’s disease is negatively associated with colon cancer risk, indicating that Parkinson’s disease family proteins may be involved in the initiation of colon cancer. Here, we aimed to identify a Parkinson’s disease-related gene involved in colon cancer, elucidate the underlying mechanisms, and test whether it can be used as a target for cancer therapy. Methods We first screened colon cancer and normal tissues for differential expression of Parkinson’s disease-associated genes and identified ATP13A2, which encodes cation-transporting ATPase 13A2, as a putative marker for colon cancer. We next correlated ATP13A2 expression with colon cancer prognosis. We performed a series of ATP13A2 knockdown and overexpression studies in vitro to identify the contribution of ATP13A2 in the stemness and invasive capacity of colon cancer cells. Additionally, autophagy flux assay were determined to explore the mechanism of ATP13A2 induced stemness. Finally, we knocked down ATP13A2 in mice using siRNA to determine whether it can be used as target for colon cancer treatment. Results Colon cancer patients with high ATP13A2 expression exhibit shorter overall survival than those with low ATP13A2. Functionally, ATP13A2 acts as a novel stimulator of stem-like traits. Furthermore, knockdown of ATP13A2 in HCT116 resulted in decreased levels of cellular autophagy. Additionally, bafilomycin A1, an autophagy inhibitor, reversed the ATP13A2-induced stemness of colon cancer cells. Lastly treatment with ATP13A2 siRNA reduced the volume of colon cancer xenografts in mice. Conclusions The PD-associated gene ATP13A2 is involved in colon cancer stemness through regulation of autophagy. Furthermore, ATP13A2 is a novel prognostic biomarker for colon cancer and is a potential target for colon cancer therapy.

MDM-2 Overexpression in Human Stem-Like and Mature Colon Cancer Cells as a Target for Anti-Cancer Therapy: Steps toward a Translational Model

2015 ◽  
Vol 221 (4) ◽  
pp. S142
Author(s):  
Mohammad F. Shaikh ◽  
Blake D. Babcock ◽  
Elizabeth Gleeson ◽  
Patrice Love ◽  
Katlin Davitt ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Therapy ◽  
Cancer Cells ◽  
Colon Cancer Cells ◽  
Translational Model ◽  
Anti Cancer

DHA Alters Expression of Target Proteins of Cancer Therapy in Chemotherapy Resistant SW620 Colon Cancer Cells

2010 ◽  
Vol 62 (5) ◽  
pp. 611-621 ◽  
Author(s):  
Jens E. Slagsvold ◽  
Caroline H. H. Pettersen ◽  
Gro L. Størvold ◽  
Turid Follestad ◽  
Hans E. Krokan ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Therapy ◽  
Cancer Cells ◽  
Colon Cancer Cells ◽  
Target Proteins

scholarly journals High aldehyde dehydrogenase activity does not protect colon cancer cells against TPCS2a-sensitized photokilling

2020 ◽  
Vol 19 (3) ◽  
pp. 308-312
Author(s):  
Judith Jing Wen Wong ◽  
Pål Kristian Selbo
Keyword(s):  
Colon Cancer ◽  
Photodynamic Therapy ◽  
Cancer Therapy ◽  
Cancer Cells ◽  
Aldehyde Dehydrogenase ◽  
Therapy Resistance ◽  
Colon Cancer Cells ◽  
Aldh Activity ◽  
Aldehyde Dehydrogenases ◽  
Aldehyde Dehydrogenase Activity

Overexpression of Aldehyde Dehydrogenases (ALDH) has been linked to cancer therapy resistance. Here we show that high ALDH activity do not cause resistance against photodynamic therapy using the PCI-photosensitizer TPCS2a/fimaporfin.

Leptin is a growth factor for human colon cancer cells

2001 ◽  
Vol 120 (5) ◽  
pp. A493-A493
Author(s):  
J HARDWICK ◽  
G VANDENBRINK ◽  
S VANDEVENTER ◽  
M PEPPELENBOSCH
Keyword(s):  
Colon Cancer ◽  
Growth Factor ◽  
Cancer Cells ◽  
Human Colon ◽  
Colon Cancer Cells ◽  
Human Colon Cancer ◽  
Human Colon Cancer Cells

Silencing of a death associated protein kinase as a pro-survival factor in colon cancer cells

Endoscopy ◽  
2005 ◽  
Vol 37 (05) ◽  
Author(s):  
GA Doherty ◽  
SM Byrne ◽  
SC Austin ◽  
GM Scully ◽  
EW Kay ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Protein Kinase ◽  
Cancer Cells ◽  
Colon Cancer Cells ◽  
Survival Factor ◽  
Death Associated Protein Kinase

Cytotoxic Effect of the Combination of Gemcitabine and Atorvastatin Loaded in Microemulsion on the HCT116 Colon Cancer Cells

2017 ◽  
Vol 9 (2) ◽  
Author(s):  
Mayson H. Alkhatib ◽  
Dalal Al-Saedi ◽  
Wadiah S. Backer
Keyword(s):  
Colon Cancer ◽  
Cancer Cells ◽  
Anticancer Drugs ◽  
Therapeutic Potential ◽  
Morphological Changes ◽  
In Vitro Study ◽  
Colon Cancer Cells ◽  
Apoptosis Detection ◽  
Hct116 Cells

The combination of anticancer drugs in nanoparticles has great potential as a promising strategy to maximize efficacies by eradicating resistant, reduce the dosage of the drug and minimize toxicities on the normal cells. Gemcitabine (GEM), a nucleoside analogue, and atorvastatin (ATV), a cholesterol lowering agent, have shown anticancer effect with some limitations. The objective of this in vitro study was to evaluate the antitumor activity of the combination therapy of GEM and ATVencapsulated in a microemulsion (ME) formulation in the HCT116 colon cancer cells. The cytotoxicity and efficacy of the formulation were assessed by the 3- (4,5dimethylthiazole-2-yl)-2,5-diphyneltetrazolium bromide (MTT) assay. The mechanism of cell death was examined by observing the morphological changes of treated cells under light microscope, identifying apoptosis by using the ApopNexin apoptosis detection kit, and viewing the morphological changes in the chromatin structure stained with 4′,6-diamidino-2-phenylindole (DAPI) under the inverted fluorescence microscope. It has been found that reducing the concentration of GEM loaded on ME (GEM-ME) from 5μM to 1.67μM by combining it with 3.33μM of ATV in a ME formulation (GEM/2ATV-ME) has preserved the strong cytotoxicity of GEM-ME against HCT116 cells. The current study proved that formulating GEM with ATV in ME has improved the therapeutic potential of GEM and ATV as anticancer drugs.

Sign in / Sign up

Export Citation Format

Share Document